International Journal of Cancer最新文献

{"title":"Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol.","authors":"Ilse A C Spiekman, Niven Mehra, Laurien J Zeverijn, Birgit S Geurts, Karlijn Verkerk, Soemeya F Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W J de Leng, Anne M L Jansen, Addy C M van de Luijtgaarden, Theo van Voorthuizen, Tineke E Buffart, Hans Gelderblom, Emile E Voest, Henk M W Verheul","doi":"10.1002/ijc.70191","DOIUrl":"https://doi.org/10.1002/ijc.70191","url":null,"abstract":"<p><p>BRCA1/2 are crucial in the homologous recombination repair (HRR) pathway, with loss-of-function (LoF) alterations predicting sensitivity to PARP-inhibitors (PARPi). Whether other HRR-gene alterations confer PARPi sensitivity remains unclear. In the Drug Rediscovery Protocol, patients receive off-label drugs matched to their tumor molecular profile. Here, olaparib efficacy and safety were evaluated in adult patients with treatment-refractory, progressive malignancies harboring LoF alterations in ATM (cohort A) or other HRR-genes including CDK12, PPP2R2A, CHEK1/2, and RAD51B (cohort B). Primary endpoints were clinical benefit (CB: confirmed objective response or stable disease ≥16 weeks) and safety. Pre-treatment biopsies were analyzed by whole-genome sequencing (WGS) for target validation. CB was observed in 8/25 patients (32%) in cohort A (prostate cancer: n = 6, adenoid cystic carcinoma: n = 1, endometrial cancer: n = 1). No effectiveness was seen in patients with colorectal cancer (n = 8). Median progression-free survival (PFS) and overall survival (OS) were 3.4 months (95% CI 1.8-5.3) and 9.2 months (95% CI 5.2-21.3), respectively. In cohort B, the CB rate was 41.7% (10/24) with median PFS and OS of 3.5 months (95% CI 3.4-6.6) and 8.1 months (95% CI 6.6-14.2), respectively. CB was observed in CKD12 (n = 7), RAD51B (n = 2), and CHEK2-altered tumors (n = 1), but not in PPP2R2A (n = 6) or CHEK1-altered tumors (n = 1). No unexpected toxicities occurred. WGS confirmed inclusion target in 84% of tested patients. In conclusion, PARPi sensitivity varies across HRR-genes, indicating that relying solely on an altered common mechanistic pathway is insufficient to predict response. Future studies should target specific HRR-genes to assess subgroup-specific benefits and determine proper use of molecular diagnostics.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145297809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total neoadjuvant therapy with six versus four cycles of CAPOX in locally advanced rectal cancer: A real-world study.","authors":"Yan-Qin Lan, Mu-Wang Hua, Sheng Peng, Xin-Li Wang, Zhang-Chi Pan, Fang-Yu Lin, Jun-Ming Chen, Dong-Ta Zhong","doi":"10.1002/ijc.70151","DOIUrl":"https://doi.org/10.1002/ijc.70151","url":null,"abstract":"<p><p>The optimal number of systemic chemotherapies for total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC) is controversial. This retrospective study, conducted at Fujian Medical University Union Hospital from January 2018 to April 2024, compared the efficacy and safety of TNT with radiotherapy plus six cycles of CAPOX (CAPOX-6, n = 105) versus four cycles of CAPOX (CAPOX-4, n = 124) in 229 patients with LARC. The CAPOX-6 group achieved a significantly higher complete response (CR) rate (53.3% vs. 28.2%, p <.001) and pathological complete remission rate (55.1% vs. 28.3%, p <.001) compared to the CAPOX-4 group. The CAPOX-6 group had higher anal preservation rates (95.9% vs. 85.8%, p = .01) and lower enterostomy rates (59.2% vs. 89.2%, p <.001). Furthermore, the CAPOX-6 group had a higher proportion of less invasive transanal local excision (35.7% vs. 4.2%, p <.001) and lower postoperative complications (12.2% vs. 23.3%, p = .04). The 2-year DFS was similar (79% for CAPOX-6 vs. 75.9% for CAPOX-4, p = .92), but the 2-year recurrence rate was significantly lower in patients achieving CR (4.2% vs. 36.7% in non-CR, p <.001). Multivariate analysis identified six cycles of CAPOX and EMVI negative as independent predictors of CR. Grade 3-4 adverse events were comparable (36% vs. 28%, p = .2), with higher grade 1-2 leukopenia, neutropenia, and neurotoxicity in the CAPOX-6 group. The study concludes that TNT with radiotherapy plus six cycles of CAPOX is a preferred treatment strategy for LARC, particularly when prioritizing organ preservation and quality of life.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145297777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results.","authors":"Francisco Hernández-Bernal, Katty-Hind Selman-Housein Bernal, Monica Bequet-Romero, Yenima Martín-Bauta, Karem M Catasús-Álvarez, Ihosvanny E Carreño-Rolando, José L Rodríguez-Reinoso, Yania L Jiménez Madrigal, Saray M López González, Yoenia Debora-Morales, Marel Alonso-Valdés, Cristina O Chávez-Chong, Gilda Lemos-Pérez, Mariela Pérez de la Iglesia, Miladys Limonta-Fernández, Verena L Muzio-González, Marta Ayala-Ávila, Yanelys Morera-Díaz","doi":"10.1002/ijc.70199","DOIUrl":"https://doi.org/10.1002/ijc.70199","url":null,"abstract":"<p><p>VEGF-driven angiogenesis fuels epithelial ovarian cancer progression, ascites, and poor prognosis. Current anti-VEGF/chemotherapy combinations provide only transient benefits with notable toxicity. HEBERSaVax, a first-in-class VEGF-targeting immunotherapy, combines recombinant VEGF-A₁₂₁ with proprietary adjuvants to generate dual anti-tumor effects: (1) neutralizing VEGF signaling via antibodies and (2) eliminating VEGF-producing cells through cytotoxic T-cell responses. We present results from the multicenter, open-label CENTAURO 4 phase 2 trial evaluating two formulations of HEBERSaVax combined with carboplatin/paclitaxel in advanced epithelial ovarian cancer patients (unresectable or suboptimal debulked). Forty patients were randomized 1:1 to receive either: Group 1: Standard chemotherapy (carboplatin/paclitaxel) plus CIGB-247 vaccine (800 μg antigen with 200 μg VSSP adjuvant) Group 2: The same chemotherapy regimen plus CIGB-247 (800 μg antigen with 0.7 mg aluminum phosphate adjuvant). The primary endpoint was progression-free survival. Secondary endpoints included objective response rate, overall survival, safety, and immune response results. HEBERSaVax exhibited excellent safety profiles and comparable immunogenicity with both adjuvant formulations. Vaccination-related adverse events were limited to grade 1-2 toxicities. Long-term outcomes showed promising clinical activity, with a median progression-free survival of 18 months and a global median overall survival of 32.82 months at 6-year follow-up. No statistically significant differences emerged between the VSSP and aluminum phosphate adjuvant formulations for either safety or efficacy endpoints. These clinical outcomes and the vaccine's favorable toxicity profile position HEBERSaVax as a promising immunotherapeutic strategy for improving epithelial ovarian cancer management.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145297839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single visit screen-triage-treat strategy using GeneXpert-based HPV testing of self-collected cervicovaginal samples and thermal ablation treatment for cervical cancer prevention among women in Lilongwe, Malawi.","authors":"Lameck Chinula, Maganizo B Chagomerana, Tawonga Mkochi, Lizzie Msowoya, Charity Nakanga, Friday Saidi, Maggie Ndovie, Coxcilly Kampani, Tamiwe Tomoka, Jennifer S Smith, Siobhan O'Connor, Victor Mwapasa, Jennifer H Tang","doi":"10.1002/ijc.70177","DOIUrl":"https://doi.org/10.1002/ijc.70177","url":null,"abstract":"<p><p>Human papillomavirus (HPV) testing is now recommended for primary screening for invasive cervical cancer (ICC) among women. We evaluated same-day completion of an HPV screen-triage-treat algorithm consisting of: (1) GeneXpert high-risk HPV testing of self-collected vaginal samples, (2) visual inspection with acetic acid (VIA) and colposcopy for HPV+ women, and (3) thermal ablation (TA) treatment for HPV+ women with acetowhite cervical lesions eligible for TA by colposcopy, in Lilongwe, Malawi. We calculated same-day completion rates of the screening algorithm as the proportion of: (a) HPV+ women who had VIA the same day, and (b) HPV+ women with ablation-eligible lesions by colposcopy who received TA the same day. Between June 2020 and February 2022, we enrolled 1250 participants: 625 women living with HIV (WLWH) and 625 without HIV. Participant median age was 35 years (IQR 30-40). A total of 698 (55.8%) had no prior ICC screening, and 589 (99.7%) of WLWH were on antiretroviral therapy. HPV DNA positivity overall was 38.1% (n = 476) and higher among WLWH (n = 295, 47.2%) than those without HIV (n = 181, 29.0%). Overall, 469 (98.5%) of the 476 HPV+ women had VIA performed. Most HPV+ women had VIA performed the same day (96%, 95% confidence interval [CI]: 94%, 98%). Similarly, most HPV+ women with ablation-eligible lesions by colposcopy received TA the same day (99%, 95% CI: 95%, 100%). VIA performed similarly to colposcopy in eligibility determination for TA. A single visit approach is achievable with an Xpert-based screen-triage-treat strategy for ICC prevention in Malawi, a reassuring finding for HPV-based primary screening scale-up.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145297866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial.","authors":"Weiming Han, Linrui Gao, Xiaomin Wang, Chen Li, Zongmei Zhou, Lei Deng, Wenqing Wang, Wenyang Liu, Xin Wang, Dongfu Chen, Qinfu Feng, Nan Bi, Tao Zhang, Jianyang Wang, Yirui Zhai, Yidian Zhao, Zefen Xiao","doi":"10.1002/ijc.70176","DOIUrl":"https://doi.org/10.1002/ijc.70176","url":null,"abstract":"<p><p>This multicenter, randomized phase III clinical trial assesses the efficacy and toxicity of SIB-RT with/without concurrent chemotherapy in patients with inoperable esophageal squamous cell carcinoma (ESCC) in the era of intensity-modulated RT and was conducted between December 2017 and November 2020. Patients with inoperable clinical stage II-III diseases or clinical stage IV disease with metastatic lymph nodes in supraclavicular/celiac trunk area were enrolled and randomized to receive SIB-RT concurrent with chemotherapy (SIB-RT + CT arm, N = 82) or SIB-RT alone (SIB-RT arm, N = 82). Planning gross tumor volume and planning target volume were administered with 59.92 and 50.4 Gy of radiation, respectively, in 28 fractions. The concurrent chemotherapy regimen comprised weekly doses of paclitaxel and nedaplatin for 5 weeks. The primary endpoint was overall survival (OS). The secondary endpoints were treatment response, progression-free survival (PFS), quality of life (QoL), and toxicity profiles. The SIB-RT + CT arm exhibited a superior treatment response to that in SIB-RT arm (69.5% vs. 53.7%, p = .04). The 5-year OS in SIB-RT arm and SIB-RT + CT arm was 23.9% vs. 28.8% (p = .33). The 5-year PFS in SIB-RT arm and SIB-RT + CT arm was 23.9% vs. 27.4% (p = .22). The improvement of EORTC QLQ-OES18 dysphagia subscale score was higher in SIB-RT + CT arm compared with SIB-RT arm (p = .02). The incidences of grade 3 or higher leukopenia and nausea were higher in SIB-RT + CT arm (p < .01 and p = .01). SIB-RT should be realized as the essential treatment modality for inoperable ESCC. SIB-RT + CT should be the preferred treatment option, as it affords a superior treatment response and greater dysphagia relief.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer screening and prevalence among older US Medicare beneficiaries with and without HIV.","authors":"Xiaoying Yu, Ornella Leukou Nzoutchoum, Daoqi Gao, Christine D Hsu, Thao N Hoang, Yong-Fang Kuo, Abbey B Berenson","doi":"10.1002/ijc.70193","DOIUrl":"https://doi.org/10.1002/ijc.70193","url":null,"abstract":"<p><p>Females with HIV (FWH) are recommended to receive cervical cancer screening annually, with the interval extended to every 3 years after three sequential normal results. Lifelong screening is highly recommended due to their increased risk of human papillomavirus infection and cervical cancer. We assessed the trends in cervical cancer screening rates and cervical cancer/precancer prevalence among older FWH and females without HIV (FWOH) using 2007-2019 US Medicare data. We found that age-adjusted cervical cancer screening rates decreased similarly in both FWH and FWOH (average annual percentage change: -4.4 [95% CI: -5.2, -3.6] vs. -5.7 [95% CI: -6.8, -4.7], p = 0.11). However, the age-adjusted cervical cancer/precancer prevalence showed increasing rates among FWH (5.4, [2.9, 7.9]) while stable in FWOH (-0.6 [-1.4, 0.1]). These findings underscore the need for strict adherence to clinical practice guidelines for cervical cancer screening in older FWH.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences of metastatic prostate cancer patients with a mainstream genetic testing pathway.","authors":"Michiel Vlaming, Eveline M A Bleiker, Gina Schijven, Lambertus A L M Kiemeney, Harm H E van Melick, Jarmo C B Hunting, M Arjen Noordzij, Aart Beeker, Diederik M Somford, Henk G van der Poel, Carl J Wijburg, Bart P Wijsman, Robert J Hoekstra, R Jeroen A van Moorselaar, Bart P J van Bezooijen, Richard P Meijer, Martijn B Busstra, H Pieter van den Berg, Debbie G J Robbrecht, Benjamin H J Doornweerd, Inge M van Oort, Margreet G E M Ausems","doi":"10.1002/ijc.70194","DOIUrl":"https://doi.org/10.1002/ijc.70194","url":null,"abstract":"<p><p>Patients with metastatic prostate cancer (mPCa) are eligible for germline genetic testing. This study assessed the experiences of mPCa patients undergoing genetic testing after being counselled by non-genetic healthcare professionals (ngHCPs: urologists, oncologists, nurses). We assessed the psychosocial impact, decision-making difficulties and knowledge of genetics. In a prospective cohort study across 15 hospitals in the Netherlands, genetic testing was discussed and requested by ngHCPs. Patients completed questionnaires shortly after receiving pre-test genetic counselling and 4 weeks and 6 months after receiving their genetic test results. Anxiety, depression, distress, decisional conflict regarding genetic testing, decision regret and knowledge of genetics were assessed. Of 767 patients who received germline genetic testing, 5% to 8% experienced clinically significant anxiety or depression at some point in time. Although up to 49% of participants had significantly elevated distress scores as assessed with the Distress Thermometer, more than 90% stated that the testing process did not affect their feelings of distress. Patients with high educational levels had more favourable outcomes than patients with low educational levels on distress and decisional conflict (odds ratios 0.36 [0.23-0.57] and 0.44 [0.21-0.93], respectively). Furthermore, only 50% of the knowledge questions about genetics were answered correctly. To conclude, germline genetic testing within a mainstreaming pathway does not lead to increased levels of general anxiety or depression in most mPCa patients. However, the poorer outcomes on several psychosocial measures for patients with low educational levels are a point of concern.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using period analysis for timely assessment and prediction of 5-year relative survival for childhood cancer patients from Taizhou, Eastern China.","authors":"Xin Bing, Asta Försti, Xiaojiao Zhao, Qiqi Lei, Liangyou Wang, Luyao Zhang, Xukai Chen, Jun Yang, Tianhui Chen","doi":"10.1002/ijc.70192","DOIUrl":"https://doi.org/10.1002/ijc.70192","url":null,"abstract":"<p><p>Timely population-based cancer registry data with accurate 5-year relative survival (RS) estimates is essential for childhood cancer control. This study analyzed survival patterns and projected future trends using data from nine cancer registries in Taizhou, Eastern China, covering patients under 15 years diagnosed during 2004-2023. Period analysis methods were employed to calculate overall and stratified 5-year RS by sex, region, age at diagnosis, and cancer types, with model-based projections for 2024-2028. The 2019-2023 overall 5-year RS reached 80.0%, showing comparable rates between females (80.8%) and males (79.6%) but significant urban-rural disparity (urban: 83.9% vs. rural: 78.6%). Survival rates followed an age-specific pattern, peaking at 84.8% in 5- to 9-year-olds before decreasing to 75.9% in 10- to 14-year-olds. Projections estimate an overall 5-year RS of 82.2% for 2024-2028. As China's first application of period analysis in childhood cancer surveillance, this study provides crucial baseline data demonstrating 80.0% 5-year RS during 2019-2023 and predicting 82.2% for 2024-2028 in Taizhou. These findings provide essential data for evaluating the effectiveness of childhood cancer early detection and screening initiatives in Eastern China. The methodology establishes a framework for ongoing survival monitoring to inform pediatric cancer control strategies.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and epidemiology of human papillomavirus-related oropharyngeal cancer in Chinese populations from 2010 to 2024.","authors":"Ruichen Li, Gulidanna Shayan, Yang Zhao, Shaoqiu Zhang, Ye Zhang, Yi Zhu","doi":"10.1002/ijc.70195","DOIUrl":"https://doi.org/10.1002/ijc.70195","url":null,"abstract":"<p><p>China's economic and societal transformations may influence cancer incidence, particularly as regional disparities shape lifestyles and sexual behaviors. This cohort study included 1002 patients, comprising 821 males (81.9%) and 181 females (18.1%), with oropharyngeal squamous cell carcinoma (OPSCC), at two medical centers in Beijing and Shanghai from 2010 to 2024. Human papillomavirus (HPV) status was assessed using p16 immunohistochemistry. The p16-positivity rate increased from 43.8% to 68.4%, reaching 57.5% overall. The proportion of p16-positive cases was significantly higher in southern China (65% vs. 51.4%) and females (83.4% vs. 51.8%) compared to northern China and males, respectively (p < 0.001). Although p16-positive cases were more frequently observed in urban areas (61% vs. 44.7%, p < 0.001), rural areas saw a significant increase from 8.3% to 62.2%. Regardless of p16 status, southern patients were generally older, had more tonsil lesions, and were at earlier stages than northern patients. p16-positive OPSCCs were more prevalent in younger individuals, with early-stage disease occurring more frequently in the tonsil compared to p16-negative ones (73.1% vs. 41.1%, p < 0.001). Recently, the burden has shifted to older men. p16-negative OPSCCs were more common in non-tonsillar regions among male smokers or drinkers. From 2010 to 2024, the p16-positive rate in tonsillar cancers increased from 48.4% to 79%, while the proportion among non-tonsil OPSCCs remained stable in males but increased significantly in females (33.3% to 80%). A substantial proportion of OPSCC cases is caused by HPV, with an increasing trend, especially in the south, underscoring the importance of vaccination programs in China.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group.","authors":"Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova","doi":"10.1002/ijc.70190","DOIUrl":"https://doi.org/10.1002/ijc.70190","url":null,"abstract":"<p><p>The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence on the concurrent administration of human epidermal growth factor receptor 2-targeted agents (trastuzumab, pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan), cyclin-dependent kinase 4 and 6 inhibitors (palbociclib, ribociclib), immunotherapies (pembrolizumab), poly(ADP-ribose) polymerase inhibitors (olaparib), and new antibody-drug conjugates (sacituzumab govitecan). Drawing from extensive clinical experience, including retrospective and prospective studies conducted at Institut Curie, this review provides a comprehensive analysis of the feasibility and safety of these novel combinations, ensuring an evidence-based approach to optimizing breast cancer treatment strategies. In addition to systemic therapy considerations, this review highlights the importance of advanced RT techniques, including proton therapy, isocentric lateral decubitus positioning, and volumetric modulated arc therapy with deep inspiration breath hold, which play a crucial role in minimizing cardiac and pulmonary toxicities, particularly in patients receiving cardiotoxic agents or those with predisposing risk factors. By integrating both systemic advancements and optimized radiation delivery, this review provides a practical framework for the safe and effective combination of modern breast cancer therapies.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}